Top ▲
Target not currently curated in GtoImmuPdb
Target id: 1985
Nomenclature: cyclin-dependent kinase like 4
Abbreviated Name: CDKL4
Gene and Protein Information ![]() |
||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 379 | 2p22.1 | CDKL4 | cyclin dependent kinase like 4 | |
Mouse | - | 342 | 17 E3 | Cdkl4 | cyclin dependent kinase like 4 | |
Rat | - | 342 | 6 q11 | Cdkl4 | cyclin-dependent kinase-like 4 |
Database Links ![]() |
|
Alphafold | Q5MAI5 (Hs), Q3TZA2 (Mm) |
BRENDA | 2.7.11.22 |
ChEMBL Target | CHEMBL4523326 (Hs) |
Ensembl Gene | ENSG00000205111 (Hs), ENSMUSG00000033966 (Mm), ENSRNOG00000040266 (Rn) |
Entrez Gene | 344387 (Hs), 381113 (Mm), 503009 (Rn) |
Human Protein Atlas | ENSG00000205111 (Hs) |
KEGG Enzyme | 2.7.11.22 |
KEGG Gene | hsa:344387 (Hs), mmu:381113 (Mm), rno:503009 (Rn) |
Pharos | Q5MAI5 (Hs) |
RefSeq Nucleotide | NM_001009565 (Hs), NM_001033443 (Mm), XM_001062504 (Rn) |
RefSeq Protein | NP_001009565 (Hs), NP_001028615 (Mm), XP_001062504 (Rn) |
UniProtKB | Q5MAI5 (Hs), Q3TZA2 (Mm) |
Wikipedia | CDKL4 (Hs) |
Enzyme Reaction ![]() |
||||
|
DiscoveRx KINOMEscan® screen ![]() |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform. http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan Reference: 1-2 |
![]() ![]() |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Target used in screen: CDKL5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Displaying the top 10 most potent ligands View all ligands in screen » |
1. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol, 29 (11): 1046-51. [PMID:22037378]
2. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem Biol, 17 (11): 1241-9. [PMID:21095574]
Cyclin-dependent kinase-like (CDKL) family: cyclin-dependent kinase like 4. Last modified on 29/01/2016. Accessed on 16/02/2025. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1985.